Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the market entry of its raw material drug, Adenosine Phosphate, which is expected to enhance its market competitiveness and create synergy with its formulation products [1]. Group 1: Product Approval - Lifesun Pharmaceutical announced the receipt of the approval notice for the market entry of Adenosine Phosphate raw material drug [1]. - Adenosine Phosphate, previously known as Vitamin B4, is a crucial component for nucleic acids and coenzymes, participating in the synthesis of DNA and RNA [1]. - The drug is clinically used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly due to chemotherapy, radiation therapy, and benzene poisoning [1]. Group 2: Market Impact - The approval of Adenosine Phosphate is expected to facilitate industrial synergy with the company's formulation products [1]. - This development is anticipated to enhance the company's market competitiveness [1].

Overview - Tianjin Lifeng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the listing application of Adenine Phosphate raw material [2] Product Information - The product, Adenine Phosphate, is a chemical raw material with a molecular weight of 233.12 and a molecular formula of C5H5N5·H3PO4 [2] - It is used clinically to prevent and treat leukopenia caused by various reasons, particularly in cases related to chemotherapy, radiation therapy, and benzene poisoning [2] Impact on the Company - The approval of this product's listing application is expected to enhance the company's market competitiveness by creating industrial synergy with its formulation products [3]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), has received approval from the National Medical Products Administration for the marketing application of Adenosine Phosphate raw material, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - Lifesun Pharmaceutical has been granted a marketing approval notice for Adenosine Phosphate raw material [1] - Adenosine Phosphate, previously known as Vitamin B4, is essential for the synthesis of DNA and RNA, playing a crucial role in maintaining metabolic functions in living organisms [1] - The clinical applications of Adenosine Phosphate include the prevention and treatment of leukopenia caused by various factors, particularly in patients undergoing chemotherapy and radiation therapy, as well as those affected by benzene poisoning [1]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of adenine phosphate raw material, which is expected to enhance its market competitiveness and create synergy with its formulation products [1] Group 1: Company Announcement - Lifesun Pharmaceutical announced the receipt of the approval notice for the listing application of adenine phosphate raw material from the National Medical Products Administration [1] - Adenine phosphate is a component of nucleic acids and coenzymes, involved in the synthesis of DNA and RNA in the body, and is clinically used to prevent and treat leukopenia caused by various reasons [1] Group 2: Market Implications - The approval of adenine phosphate raw material is expected to facilitate industrial synergy with the company's formulation products, thereby enhancing market competitiveness [1]

证券代码：002393 证券简称：力生制药 公告编号：2026-011 天津力生制药股份有限公司 关于磷酸腺嘌呤原料药通过上市申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于磷酸腺嘌呤原料药《化学原料药上市申请批准通知书》（通知书编号： 2026YS00104），该品种通过化学原料药上市申请。 二、该品种的基本情况 通用名称：磷酸腺嘌呤 英文名称：Adenine Phosphate 汉语拼音：Linsuan Xianpiaoling 化学名：6-氨基嘌呤磷酸盐 化学结构式： 分子量：233.12 分子式：C5H5N5·H3PO4 CAS 号：70700-30-0 生产企业：天津力生制药股份有限公司 申请内容：化学原料药上市申请 受理号：CYHS2460726 审批结论：通过化学原料药上市申请 1 三、该品种的相关信息 天津力生制药股份有限公司 董事会 2026 年 2 月 7 日 2 磷酸腺嘌呤，曾用名维生素 B4，为核酸和辅酶的组成成分，参与体内 DN ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至本公告日，天津力生制药股份有限公司（以下简称"公司"或"本公司"）回购专 用证券账户持股数量为699,980股，根据《中华人民共和国公司法》《深圳证券交易所上市 公司自律监管指引第9号——回购股份》等相关规定，该部分股票不参与本次利润分配。公 司以现有总股本257,586,843股扣除已回购库存股699,980股后的256,886,863股为基数，向 全体股东每10股派3.00元人民币（含税），不送红股，不以公积金转增股本。 2、因公司回购专户的股份不参与2025年前三季度权益分派，本次实际现金分红的总金 额=实际参与分配的总股本*分配比例，即256,886,863股*0.30元/股=77,066,058.90元人民 币；本次权益分派实施后除息价格计算时，每股现金红利应以0.2991847元/股计算（每股现 金红利=现金分红总额/总股本，即77,066,058.90元÷257,586,843股=0.2991847元/股，计算 结果不四舍五入，保留小数点后七位）。在保证本次权益分派方案不变的前提 ...

之 法律意见书 关于 天津力生制药股份有限公司2026年第一次临时股东会 天津市四方君汇律师事务所 Join & High Law Office 关于天津力生制药股份有限公司 2026 年第一次临时股东会之法律意见书 致：天津力生制药股份有限公司 天津四方君汇律师事务所（以下简称"本所"）接受天津力生制药股份有限公司（以下简 称"公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范性文件（以下简称 "法律、法规"）以及《天津力生制药股份有限公司章程》（以下简称"《公司章程》"）有 关规定，就公司召开 2026 年第一次临时股东会（以下简称"本次股东会"）有关事宜出具本 法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合法律、法规及《公司章程》规定，以及表决结果是否合法有效发表 意见，并不对本次股东会所审议的议案内容以及该等议案所表述的相关事实的真实性、准确性 或合法性发表意见。 为出具本法律意见书，本所律师审查了本次股东会相关的文件、资料，并对本次股 ...

天津力生制药股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2026-009 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议：2026年2月2日（星期一）下午3:30开始 （2）网络投票：2026年2月2日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2026年2月2日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2026年2月2日9:15～15:00期间的任意时间。 （二）会议出席情况 | 分类 | 人数 | 代表股数（股） | 占公司有表决权股份总数的比例（%） | | --- | --- | --- | --- | | 1.总体出席情况 | 145 | 140,648 ...

天津力生制药股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于近日收到渤海证券 股份有限公司（以下简称"渤海证券"）出具的《关于变更力生制药IPO项目持续督导保 荐代表人的通知》，具体情况如下： 渤海证券为天津力生制药股份有限公司IPO项目持续督导保荐机构，因募集资金尚 未使用完毕，渤海证券仍就剩余募集资金的使用情况继续履行持续督导责任。 由于原指派的保荐代表人张运发先生正常办理退休，不再担任公司持续督导的保荐 代表人，为保证持续督导工作的有序进行，渤海证券决定指派保荐代表人张化先生接替 其持续督导工作，履行保荐职责。本次变更后，天津力生制药股份有限公司IPO项目持 续督导的保荐代表人为方万磊先生和张化先生。 公司董事会对张运发先生在担任保荐代表人期间所做的工作表示衷心感谢！ 特此公告。 证券代码：002393 证券简称：力生制药 公告编号：2026-008 天津力生制药股份有限公司 关于变更持续督导保荐代表人的公告 2026 年 01 月 31 日 附张化先生简历： 张化先生，保荐 ...